Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 168-176

  Jungkunz Stier, Isabel ^a   Zekl, Michael ^a   Stühmer, Thorsten ^a   Einsele, Hermann ^a   Seggewiss Bernhardt, Ruth ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Dasatinib; IMiD ; Lenalidomide; Multiple myeloma; NK cell; Tyrosine kinase inhibitor

Indexed keywords

DASATINIB; GAMMA INTERFERON; LENALIDOMIDE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CELL EXPANSION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; DRUG POTENTIATION; DRUG RESPONSE; EFFECTOR CELL; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION;

APOPTOSIS; CELL DEGRANULATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; KILLER CELLS, NATURAL; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2; MULTIPLE MYELOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THALIDOMIDE; THIAZOLES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84891366936     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.794270     Document Type: Article

References (48)

1. Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105: 251-258.
2. Gabriel IH, Sergeant R, Szydlo R, et al. Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood. 2010; 116: 2033-2039.
3. Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011; 117: 1605-1613.
4. Ritchie DS, Quach H, Fielding K, et al. Drug-mediated and cellular immunotherapy in multiple myeloma. Immunotherapy. 2010; 2: 243-255.
5. Godfrey J, Benson DM Jr. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma 2012; 53: 1666-1676.
6. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24: 22-32.
7. Davies FE, Raje N, Hideshima T, et al. Th alidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
8. Tai YT, Li XF, Catley L, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications. Cancer Res 2005; 65: 11712-11720.
9. Lioznov M, El-Cheikh J. Jr, Hoffmann F, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44 (-) ) and T (HLA-DR (-) ) cells. Bone Marrow Transplant 2010; 45: 349-353.
10. Scott LJ, Lyseng-Williamson KA. Lenalidomide: A review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 2011; 71: 625-649.
11. Hassold N, Seystahl K, Kempf K, et al. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int J. Cancer 2012; 131: E916-E927.
12. Kreutzman A, Ladell K, Koechel C, et al. Expansion of highly differentiated CD8 (-) T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011; 25: 1587-1597.
13. Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009; 94: 135-139.
14. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23: 1398-1405.
15. Mesecke S, Urlaub D, Busch H, et al. Integration of activating and inhibitory receptor signaling by regulated phosphorylation of Vav1 in immune cells. Sci Signal 2011; 4: Ra36.
16. Podar K, Mostoslavsky G, Sattler M, et al. Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells. J. Biol Chem 2004; 279: 21658-21665.
17. Ishikawa H, Tsuyama N, Abroun S, et al. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood 2002; 99: 2172-2178.
18. Ishikawa H, Tsuyama N, Abroun S, et al. Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation. Leuk Lymphoma 2003; 44: 1477-1481.
19. Coluccia AM, Cirulli T, Neri P, et al. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: Preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood. 2008; 112: 1346-1356.
20. Wildes TM, Procknow E, Gao F, et al. Dasatinib in relapsed or plateau-phase multiple myeloma. Leuk Lymphoma 2009; 50: 137-140.
21. Weisberg E, Manley PW, Cowan-Jacob SW, et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345-356.
22. Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 2013; 62: 39-49.
23. Weichsel R, Dix C, Wooldridge L, et al. Profound inhibition of antigen-specifi c T-cell effector functions by dasatinib. Clin Cancer Res 2008; 14: 2484-2491.
24. Stü h mer T, Arts J, Chatterjee M, et al. Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. Br J. Haematol 2010; 149: 529-536.
25. Janz M, Stühmer T, Vassilev LT, et al. Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/ Reed-Sternberg cells. Leukemia 2007; 21: 772-779.
26. Siegmund D, Wicovsky A, Schmitz I, et al. Death receptor-induced signaling pathways are differentially regulated by gamma interferon upstream of caspase 8 processing. Mol Cell Biol 2005; 25: 6363-6379.
27. Gomez-Roman VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, et al. A simplifi ed method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol Methods 2006; 308: 53-67.
28. Valiante NM, Rengaraju M, Trinchieri G. Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B cell lines to stimulate T and NK cell proliferation. Cell Immunol 1992; 145: 187-198.
29. Baltz KM, Krusch M, Bringmann A, et al. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J. 2007; 21: 2442-2454.
30. Mainiero F, Soriani A, Strippoli R, et al. RAC1/P38 MAPK signaling pathway controls beta1 integrin-induced interleukin-8 production in human natural killer cells. Immunity 2000; 12: 7-16.
31. Bryceson YT, March ME, Barber DF, et al. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J. Exp Med 2005; 202: 1001-1012.
32. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specifi c CD8-T cells by a fl ow cytometric assay for degranulation. J. Immunol Methods 2003; 281: 65-78.
33. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application. Br J. Haematol 2005; 128: 192-203.
34. Smyth MJ, Cretney E, Kelly JM, et al. Activation of NK cell cytotoxicity. Mol Immunol 2005; 42: 501-510.
35. Caligiuri MA. Human natural killer cells. Blood 2008; 112: 461-469.
36. Dirks W, Schone S, UphoffC, et al. Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines. Br J. Haematol 1997; 96: 584-593.
37. Balsas P, Lopez-Royuela N, Galan-Malo P, et al. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem Pharmacol 2009; 77: 804-812.
38. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications. Blood 2001; 98: 795-804.
39. Gazitt Y, Shaughnessy P, Montgomery W. Apoptosis-induced by TRAIL and TNF-Alpha in human multiple myeloma cells is not blocked by BCL-2. Cytokine 1999; 11: 1010-1019.
40. Benson D M Jr, Bakan CE, Zhang S, et al. IPH2101, anovel antiinhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 2011; 118: 6387-6391.
41. Menoret E, Gomez-Bougie P, Geffroy-Luseau A, et al. Mcl-1L cleavage is involved in TRAIL-R1-And TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood. 2006; 108: 1346-1352.
42. Gomez-Benito M, Martinez-Lorenzo MJ, Anel A, et al. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 2007; 313: 2378-2388.
43. Rauert H, Stühmer T, Bargou R, et al. TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms. Cell Death Dis 2011; 2: E194.
44. De Queiroz Crusoe E, Maiso P, Fernandez-Lazaro D, et al. Transcriptomic rationale for the synergy observed with dasatinib -bortezomib-dexamethasone in multiple myeloma. Ann Hematol 2012; 91: 257-269.
45. Steinbrunn T, Stühmer T, Sayehli C, et al. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. Br J. Haematol 2012; 159: 430-440.
46. Zöl linger A, Stü h mer T, Chatterjee M, et al. Combined functional and molecular analysis of tumor cell signaling defi nes 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 2008; 112: 3403-3411.
47. Berg M, Lundqvist A, McCoy P Jr, et al. Clinical-grade ex vivoexpanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009; 11: 341-355.
48. Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology 2009; 127: 145-154.